Palvella Therapeutics, Inc.(PVLA:US)
Market Cap$1.732B
Key Metrics
Price$120.30
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$61.7M
EBITDA (TTM)-$53.65M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$187.8M
Total Assets$253.51M
Net Assets$216.87M
Total Debt$535K
Key Metrics
Price$120.30
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$61.7M
EBITDA (TTM)-$53.65M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$187.8M
Total Assets$253.51M
Net Assets$216.87M
Total Debt$535K
Financials
| Name | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 | - | - | - | - | - | - | $0 |
Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| $21.41M | $14.86M | $11.3M | $10.18M | - | - | - | - | - | - | $4.54M | |
| Research and Development | $12.47M | $9.33M | $7.12M | $6.53M | - | - | - | - | - | - | $3.62M |
| Selling, General, and Administrative | $8.93M | $5.52M | $4.18M | $3.65M | - | - | - | - | - | - | $924K |
| Other Operating Expenses | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | -$21.41M | -$14.86M | -$11.3M | -$10.18M | - | - | - | - | - | - | -$4.54M |
| -$465K | -$912K | -$1.41M | -$1.17M | - | - | - | - | - | - | -$2.17M | |
| Non-Operating Interest Income | $1.97M | $1.07M | $520K | $628K | - | - | - | - | - | - | - |
| Non-Operating Interest Expense | $2.31M | $2.04M | $1.74M | $1.51M | - | - | - | - | - | - | $2.58M |
| Other Income/Expense | -$122K | $54K | -$191K | -$286K | - | - | - | - | - | - | $407K |
Income Before Tax | -$21.87M | -$15.77M | -$12.71M | -$11.35M | - | - | - | - | - | - | -$6.71M |
Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Net Income | -$21.87M | -$15.77M | -$12.71M | -$11.35M | - | - | - | - | - | - | -$6.71M |
Minority Interests | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -$21.87M | -$15.77M | -$12.71M | -$11.35M | - | - | - | - | - | - | -$6.71M |
Shares Outstanding (Basic) | 14.36M | 13.09M | - | 11.06M | 11.05M | 11.01M | - | - | 11.22M | 11.22M | 11.22M |
Shares Outstanding (Diluted) | 14.36M | 13.09M | - | 11.06M | 11.05M | 11.01M | - | - | 11.22M | 11.22M | 11.22M |
EPS (Basic) | -$1.52 | -$1.20 | - | -$1.03 | -$0.86 | -$0.74 | - | - | -$0.39 | -$0.24 | -$0.62 |
EPS (Diluted) | -$1.52 | -$1.20 | - | -$1.03 | -$0.86 | -$0.74 | - | - | -$0.39 | -$0.24 | -$0.62 |
EBIT | -$19.56M | -$13.73M | -$10.98M | -$9.84M | - | - | - | - | - | - | -$4.13M |
EBITDA | -$19.45M | -$13.81M | -$10.88M | -$9.52M | - | - | - | - | - | - | -$4.05M |